Thank you to @SFBusinessTimes' @rleuty_biotech for reporting on a major milestone: @DispatchBio has dosed its first patient in a Phase 1 clinical trial of DISP-10, a novel approach to treating solid tumors.
Born out of a 2021 Parker Institute retreat, Dispatch brings together
